Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
73 USD | -1.13% | -3.29% | -1.17% |
05:25pm | Bernstein Adjusts Centene's Price Target to $94 From $100 | MT |
01:26pm | Deutsche Bank Adjusts Price Target on Centene to $82 From $81 | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.29 for the 2024 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.17% | 39.4B | B- | ||
-8.14% | 450B | B- | ||
+12.46% | 124B | A- | ||
+19.29% | 101B | B- | ||
-33.90% | 36.53B | A- | ||
-5.85% | 20.15B | B- | ||
-13.23% | 3.13B | C+ | ||
-39.90% | 969M | B- | ||
-31.04% | 334M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CNC Stock
- Ratings Centene Corporation